253 related articles for article (PubMed ID: 34887574)
1. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW; Lorentzen CL; Martinenaite E; Ellebaek E; Donia M; Holmstroem RB; Klausen TW; Madsen CO; Ahmed SM; Weis-Banke SE; Holmström MO; Hendel HW; Ehrnrooth E; Zocca MB; Pedersen AW; Andersen MH; Svane IM
Nat Med; 2021 Dec; 27(12):2212-2223. PubMed ID: 34887574
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab.
Lorentzen CL; Kjeldsen JW; Ehrnrooth E; Andersen MH; Marie Svane I
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217243
[TBL] [Abstract][Full Text] [Related]
3. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
4. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
[TBL] [Abstract][Full Text] [Related]
5. Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.
Jørgensen NG; Klausen U; Grauslund JH; Helleberg C; Aagaard TG; Do TH; Ahmad SM; Olsen LR; Klausen TW; Breinholt MF; Hansen M; Martinenaite E; Met Ö; Svane IM; Knudsen LM; Andersen MH
Front Immunol; 2020; 11():595035. PubMed ID: 33240282
[TBL] [Abstract][Full Text] [Related]
6. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
7. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.
Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K
Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303
[TBL] [Abstract][Full Text] [Related]
8. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
9. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
Bjoern J; Iversen TZ; Nitschke NJ; Andersen MH; Svane IM
Cytotherapy; 2016 Aug; 18(8):1043-1055. PubMed ID: 27378345
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Jung HA; Park KU; Cho S; Lim J; Lee KW; Hong MH; Yun T; An HJ; Park WY; Pereira S; Ock CY; Keam B
Clin Cancer Res; 2022 Oct; 28(19):4240-4247. PubMed ID: 35819451
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N
Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908
[No Abstract] [Full Text] [Related]
13. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Placke JM; Kimmig M; Griewank K; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Welzel J; Engel DR; Kreft S; Sucker A; Lodde G; Krefting F; Stoffels I; Klode J; Roesch A; Zimmer L; Livingstone E; Hadaschik E; Becker JC; Weichenthal M; Tasdogan A; Schadendorf D; Ugurel S
EBioMedicine; 2023 Oct; 96():104774. PubMed ID: 37660535
[TBL] [Abstract][Full Text] [Related]
14. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
[TBL] [Abstract][Full Text] [Related]
15. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
Shimoda Y; Yoshida T; Shirasawa M; Mizuno T; Jo H; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y; Motoi N
Anticancer Res; 2021 Nov; 41(11):5739-5747. PubMed ID: 34732447
[TBL] [Abstract][Full Text] [Related]
16. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
Zahm CD; Johnson LE; McNeel DG
Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
[TBL] [Abstract][Full Text] [Related]
17. Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.
Kim AK; Gani F; Layman AJ; Besharati S; Zhu Q; Succaria F; Engle EL; Bhaijee F; Goggins MB; Llosa NJ; Pawlik TM; Yarchoan M; Jaffee EM; Simons HC; Taube JM; Anders RA
Cancer Immunol Res; 2019 May; 7(5):805-812. PubMed ID: 30902819
[TBL] [Abstract][Full Text] [Related]
18. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.
Seeber A; Klinglmair G; Fritz J; Steinkohl F; Zimmer KC; Aigner F; Horninger W; Gastl G; Zelger B; Brunner A; Pichler R
Cancer Sci; 2018 May; 109(5):1583-1591. PubMed ID: 29498788
[TBL] [Abstract][Full Text] [Related]
19. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma].
Liu HQ; Zou BQ; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692
[No Abstract] [Full Text] [Related]
20. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]